Bristol-Myers Squibb Option Alert: Aug 15 $45 Calls Sweep (45) near the Ask: 6974 vs 2288 OI

Bristol-Myers Squibb Option Alert: Aug 15 $45 Calls Sweep (45) near the Ask: 6974 @ $0.8 vs 2288 OI; Ref=$44.25

Bristol-Myers Squibb (NYSE:BMY) Stock

BRISTOL-MYERS SQUIBB CO

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Citigroup analyst Andrew Baum maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and lowers the price target from $51 to $47.

News

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $47

President&nbsp;Donald Trump&nbsp;has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.
<h2 class="wp-block-heading">President Threatens Action Over &#8216;Abusive Drug Pricing Practices,&#8217; Issues Deadline to Commit</h2>
Trump, on Thursday, posted individual letters he sent to companies including AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) on his social media platform.
Trump warned that if the companies do not comply, he will use &#8220;every tool in our arsenal&#8221; to safeguard American families from &#8220;continued abusive drug pricing practices.&#8221; The companies have been given until September 29 to commit to his goals.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="443" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01023355/image-2.png" alt="" class="wp-image-1010260" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01023355/image-2.png 443w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01023355/image-2-240x300.png 240w" sizes="(max-width: 443px) 100vw, 443px" /></figure>
Trump&#8217;s letters on Thursday took aim at the drugmakers&#8217; proposed solutions to address high U.S. drug prices, calling them &#8220;more of the same: shifting blame and requesting policy changes that would result in billions of dollars in handouts to the industry.&#8221;
<h2 class="wp-block-heading">Trump Pushes for Global Benchmark Pricing, Middleman-Free Drug Sales</h2>
Trump urged drugmakers to offer all existing drugs to Medicaid patients at the lowest prices available in other developed countries, adopt most-favored-nation pricing for all new drugs across Medicare, Medicaid, and commercial payers, and push back against "foreign freeloading nations" in pricing negotiations. He also called for direct-to-consumer or business sales models to eliminate middlemen and ensure Americans receive globally competitive prices.
In May, he announced a <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">&#8220;most favored nations&#8221; policy</a>, requiring pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country. This policy could result in price cuts of up to 80% for some drugs.
SEE ALSO: <a href="https://benzinga.com/markets/macro-economic-events/25/07/46781078/peter-schiff-slams-feds-blind-spot-jerome-powell-looking-through-soaring-inflation-" target="_blank" rel="noreferrer noopener">Peter Schiff Slams Fed&#8217;s Blind Spot: Jerome Powell &#8216;Looking Through&#8217; Soaring Inflation While Policy Remains &#8216;Far Too Loose&#8217;</a>
<h2 class="wp-block-heading">U.S.-EU Tariffs, Pharma Pushback Pose Roadblock To US Drug Price Reform</h2>
The U.S. pharmaceutical industry is facing significant financial challenges. A new <a href="https://www.benzinga.com/news/topics/25/07/46686877/drug-prices-to-get-more-expensive-under-trumps-eu-trade-deal-as-pharma-faces-billions-in-added-costs-report">trade deal </a>between the U.S. and the European Union is set to impose a 15% tariff on branded drugs imported from Europe, potentially leading to increased drug prices and restricted access for consumers.
Despite the challenges, some pharmaceutical companies are optimistic about <a href="https://www.benzinga.com/news/25/07/46639976/3-pharma-stocks-that-arent-sweating-the-coming-200-drug-tariffs">finding solutions</a> to help Americans access and afford the drugs they need. Previously, Pfizer, Novo Nordisk, and Novartis have all stated that they are working on potential solutions, with Pfizer describing its discussions with the Trump administration and Congress as &#8220;productive.&#8221;
However, the industry&#8217;s largest lobbying group, PhRMA, has warned that importing <a href="https://www.benzinga.com/news/topics/25/07/46686877/drug-prices-to-get-more-expensive-under-trumps-eu-trade-deal-as-pharma-faces-billions-in-added-costs-report">foreign price</a> controls could undermine American leadership, hurting patients and workers. The group has called for U.S. officials to &#8220;rein in health care middlemen driving up costs for Americans and get foreign countries to pay their fair share for innovative medicines.&#8221;
Price Action: Shares of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Merck &amp; Co Inc. and Eli Lilly And Co. declined 5.92%, 4.44% and 2.63%, respectively, during Thursday&#8217;s trading session.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46756486/eli-lilly-obesity-drug-mounjaro-beats-legacy-trulicity-on-cardio-renal-health">Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ABBV

AMGN

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'

Investors with a lot of money to spend have taken a bullish stance on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BMY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 42 uncommon options trades for Bristol-Myers Squibb.
This isn't normal.
The overall sentiment of these big-money traders is split between 59% bullish and 33%, bearish.
Out of all of the special options we uncovered, 26 are puts, for a total amount of $1,771,839, and 16 are calls, for a total amount of $839,064.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $55.0 for Bristol-Myers Squibb over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bristol-Myers Squibb's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bristol-Myers Squibb's substantial trades, within a strike price spectrum from $25.0 to $55.0 over the preceding 30 days.
<h3>Bristol-Myers Squibb Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753992086_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.75</td>
<td>$47.00</td>
<td>$199.1K</td>
<td>8.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$2.12</td>
<td>$1.93</td>
<td>$1.93</td>
<td>$44.00</td>
<td>$193.0K</td>
<td>9</td>
<td>1.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$2.71</td>
<td>$2.62</td>
<td>$2.62</td>
<td>$45.00</td>
<td>$132.8K</td>
<td>17</td>
<td>519</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.19</td>
<td>$1.18</td>
<td>$1.18</td>
<td>$44.00</td>
<td>$119.0K</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$2.16</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$47.00</td>
<td>$106.2K</td>
<td>770</td>
<td>1</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Bristol-Myers Squibb Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 31,968,844, the BMY's price is down by -5.55%, now at $43.43. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>What Analysts Are Saying About Bristol-Myers Squibb</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $34.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Underweight rating for Bristol-Myers Squibb, targeting a price of $34. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Bristol-Myers Squibb Unusual Options Activity For July 31

A post-earnings surge in Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) sent major tech-heavy indices to fresh record highs Thursday, capping a fourth consecutive month of <a href="https://www.benzinga.com/markets/tech/25/07/46760627/magnificent-seven-microsoft-meta-nvdia-earnings-sp500-market-cap">gains for U.S. equities.</a>
By midday in New York, the S&amp;P 500 rose 0.7% to break above 6,400, while the Nasdaq 100 climbed past 24,500 — each logging new intraday highs.
Meta jumped 11% after delivering blockbuster second-quarter results and upbeat revenue guidance. Microsoft climbed about 5% after reporting strong Azure revenues.
The combined market value of the Magnificent Seven swelled past $19.4 trillion, with both Microsoft and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/markets/tech/25/07/46760627/magnificent-seven-microsoft-meta-nvdia-earnings-sp500-market-cap">worth more than $4 trillion</a>.
Indexes with less tech exposure lagged: the Dow Jones added just 0.1%, while the Russell 2000 slipped 0.1%.
The broader market surge came despite hotter-than-expected inflation data that supported the Federal Reserve's decision to keep interest rates steady in July.
The Personal Consumption Expenditures (PCE) price index rose to 2.6% in June from 2.3% in May, surpassing the 2.5% forecast. Core PCE, the Fed's preferred inflation gauge, held at 2.8%, <a href="https://www.benzinga.com/markets/economic-data/25/07/46755543/inflation-pce-june-tariffs-trump-powell-interest-rates">above the 2.7% consensus.</a>
Traders are now pricing in just a 39% chance of a rate cut in September, according to the CME FedWatch Tool, down from 65% earlier this week.
On trade, President Donald Trump announced a new 15% tariff on select South Korean imports, while a deal with Mexico was extended for another 90 days.
The U.S. dollar index gained 0.1%, aiming for its sixth straight daily gain and the longest winning streak since 2022. 
Commodities remained under pressure. Copper fell another 5% to $4.39 per pound, nearing April's lows after Wednesday's historic 19.4% drop triggered by tariff exemptions on refined copper.
Silver lost 1.3%, while gold edged up 0.5% to $3,290 per ounce. 
In crypto, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 0.9% to $118,871.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg. %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,406.83</td>
<td>0.7%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,495.60</td>
<td>0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,550.87</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,229.94</td>
<td>-0.1 %</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.6% to $586.59.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% up to $444.99.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.5% to $570.89.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.2% to $221.21.</li>
<li>The&nbsp;Communication Services&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 1.6%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.7%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Stocks moving on earnings reports included: 
<ul class="wp-block-list">
<li>Microsoft Corp. up 4.5%</li>
<li>Meta Platforms, Inc. up 12.3%</li>
<li>Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) up 3.0%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) up 2.5%</li>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) up 4.3%</li>
<li>QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) down 6.2%</li>
<li>KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) down 2.4%</li>
<li>Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) up 2.4%</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) down 4.5%</li>
<li>Intercontinental Exchange, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) up 0.4%</li>
<li>The Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) up 0.3%</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) down 4.6%</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) up 18.2%</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) up 1.6%</li>
<li>Equinix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) up 0.9%</li>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) down 6%</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) down 9.5%</li>
<li>Air Products and Chemicals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) down 0.6%</li>
<li>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) down 2.6%</li>
<li>Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) up 6.7%</li>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) down 4.8%</li>
<li>Exelon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) up 1.1%</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) up 2.5%</li>
<li>AMETEK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) up 5.9%</li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) up 18.6%</li>
<li>Xcel Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) up 1.5%</li>
<li>Prudential Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) up 3%</li>
<li>Cognizant Technology Solutions Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) up 0.1%</li>
<li>Vulcan Materials Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) down 0.7%</li>
<li>VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>) up 1.5%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) up 9.3%</li>
<li>Fair Isaac Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) down 11.1%</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) down 6.7%</li>
<li>Willis Towers Watson Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) up 5.0%</li>
<li>Blue Owl Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) down 0.7%</li>
<li>PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) down 0.8%</li>
<li>Ventas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) up 1.1%</li>
<li>Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) down 8.1%</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) up 0.1%</li>
<li>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) down 0.6%</li>
<li>American Water Works Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) up 1.0%</li>
<li>AvalonBay Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) down 2.9%</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 8.7%</li>
<li>PPL Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) down 0.7%</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) up 7.6%</li>
<li>International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) down 8.9%</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) up 4.9%</li>
<li>FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) up 1.5%</li>
<li>Invitation Homes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) down 0.7%</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) up 1.8%</li>
<li>GFL Environmental Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) up 5.6%</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) up 6.8%</li>
<li>Mid-America Apartment Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) down 2.0%</li>
<li>Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) up 4.2%</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) down 3.4%</li>
<li>Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) up 2.6%</li>
<li>Kimco Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) down 0.9%</li>
<li>Everest Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) up 2.0%</li>
<li>Masco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) up 3.9%</li>
<li>XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) down 8.9%</li>
<li>UDR, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) flat at -0.0%</li>
<li>C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) up 17.1%</li>
<li>Builders FirstSource, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) down 2.8%</li>
<li>Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) down 19.1%</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) up 8.9%</li>
<li>Host Hotels &amp; Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) down 1.5%</li>
<li>Huntington Ingalls Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) up 9.9%</li>
<li>Antero Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) up 2.7%</li>
<li>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) down 4.1%</li>
</ul>
Stocks slated to report earnings after the close include: Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), KLA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), Roper Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NYSE">ROP</a>), Monolithic Power Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>), Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>), AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>), Vale S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>), The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>), ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>), Ameren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>), Essential Utilities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>), Camden Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>), Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>), Northern Oil and Gas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>), Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>), Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>), Rogers Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>), Ryan Specialty Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>), and Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>).
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46733603/fed-holds-trump-powell-waller-bowman-interest-rates">Fed Skips Rate Cut Again—But Reveals Something We Haven&#8217;t Seen Since 1993</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Trading Ideas

ETFs

$BTC

AAPL

AMZN

APTV

BIIB

BLDR

CHRW

CMCSA

COIN

CTSH

CVNA

SPDR Dow Jones Industrial Average ETF Trust

DXCM

EBAY

EQIX

FFIV

FICO

FSLR

HOLX

INVH

KLAC

LPLA

LRCX

MELI

MPWR

MSFT

NCLH

NVDA

PCOR

QCOM

ROKU

RYAN

SPGI

VALE

VICI

Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?

Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) reported second-quarter 2025 revenues of $12.27 billion, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the&nbsp;consensus of $11.31 billion</a>, almost flat year over year.
U.S. sales slipped 3% to $8.5 billion, while international revenues climbed 10% to $3.8 billion, representing an 8% increase when excluding foreign exchange impacts (Ex-FX).
Growth Portfolio revenues of $6.6 billion <a target="_blank" href="https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2025/BMY-Q2-2025-Earnings-Press-Release.pdf" rel="noreferrer noopener">increased</a> 18%, or 17% Ex-FX. Revenue growth was primarily driven by the immuno-oncology (IO) portfolio, Breyanzi, Reblozyl, and Camzyos, reflecting the continued strength of Cobenfy <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">(a schizophrenia drug)</a>.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46400278/is-bristol-myers-squibb-still-an-undervalued-biopharma-play" target="_blank" rel="noreferrer noopener">Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?</a>
Sales of the cancer drug Opdivo increased 7% to $2.56 billion. The arthritis drug Orencia generated sales of $963 million, up 2%. Sales of another cancer drug, Yervoy, increased 16% to $728 million. 
Camzyos (a heart drug) generated sales of $260 million, up 87%. The anemia drug Reblozyl generated $568 million in quarter sales, up 34% from a year ago.
Legacy Portfolio revenues of $5.7 billion decreased 14%, or 15% Ex-FX. Demand increased for Eliquis, offset by expected continued generic impact across the remainder of the Legacy Portfolio and the impacts from the U.S. Medicare Part D redesign.
Bristol-Myers reported adjusted earnings of $1.46 per share, missing the consensus of $1.58. GAAP EPS was 64 cents and non-GAAP EPS was $1.46. Both figures include the net impact of 57 cents due to the Acquired IPRD charge associated with the BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) <a href="https://www.benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug" target="_blank" rel="noreferrer noopener">strategic partnership worth $11 billion</a>.
Gross margin decreased from 73.2% to 72.5% on a GAAP basis, and from 75.6% to 72.6% on a non-GAAP basis, primarily due to product mix.
<h2 class="wp-block-heading">Outlook</h2>
Bristol Myers Squibb lowered its fiscal 2025 adjusted earnings guidance from $6.70-$7.00 to $6.35-$6.65 per share compared to the consensus of $6.76.
The US drugmaker raised 2025 sales guidance <a href="https://www.benzinga.com/general/biotech/25/04/44986472/bristol-myers-delivers-upbeat-2025-forecast-after-beating-q1-wall-street-expectations-says-guidance-includes-china-tariffs-impact" target="_blank" rel="noreferrer noopener">from $45.8 billion-$46.8 billion</a> to $46.5 billion-$47.5 billion compared to the consensus of $46.23 billion. It reiterated gross margin guidance of around 72%.
On Monday, Bristol Myers and Bain Capital announced the creation of a new independent biopharmaceutical company focused on developing new therapies for autoimmune diseases.
The newly formed company launches with five immunology assets in-licensed from Bristol Myers and a $300 million financing commitment that <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46673552/bristol-myers-squibb-and-bain-capital-create-new-company-dedicated-to-developing-innovative-immuno" rel="noreferrer noopener">Bain Capital led</a>.
Price Action: BMY stock is trading lower by 3.04% to $44.58 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46748673/jensen-huang-sells-39-million-in-shares-as-nvda-stock-soars-30-in-2025" target="_blank" rel="noreferrer noopener">Jensen Huang Sells $39 Million In Shares As NVDA Stock Soars 30% In 2025</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Guidance

Health Care

Movers

General

BNTX

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

WIIM

BMY stock has given up its prior gain. Bristol-Myers Squibb shares were trading higher after the company reported a Q2 sales beat and raised its FY25 sales guidance above estimates.

Bristol-Myers Squibb shares are trading higher after the company reported a Q2 sales beat and raised its FY25 sales guidance above estimates.

Financial Guidance Bristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $45.8 billion to $46.8 billion, to a range of approximately $46.5 billion to $47.5 billion, reflecting the strength of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the second quarter, and a favorable impact of approximately $200 million related to foreign exchange rates. Full-year operating expense expectations are now approximately $16.5 billion, reflecting the investment behind recent business development transactions and the identification of additional investment opportunities within our Growth Portfolio. The company now anticipates other income and expense in 2025 to be approximately $250 million of income due to higher-than-anticipated royalties and favorable interest income.&nbsp;
Non-GAAP EPS is now expected to be in the range of $6.35 - $6.65, inclusive of an unfavorable $(0.57) per share impact from the BioNTech Acquired IPRD charge this quarter.
&nbsp;

Bristol-Myers Squibb Lowers FY2025 Adj EPS Guidance from $6.70-$7.00 to $6.35-$6.65 vs $6.76 Est; Raises FY2025 Sales Guidance from $45.800B-$46.800B to $46.500B-$47.500B vs $46.229B Est

Bristol-Myers Squibb Q2 2025 Adj. EPS $1.46 Misses $1.58 Estimate, Sales $12.300B Beat $11.310B Estimate

U.S. stock futures rose on Thursday after ending on a mixed note on Wednesday. Futures of major benchmark indices were higher, except for the small-cap gauge Russell 2000.
President Donald Trump announced on Wednesday that the United States has reached a "<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46744534/trump-pleased-with-450b-south-korea-tariff-deal-seoul-to-accept-us-cars-agriculture-economist-warns-americans-pay-the-15-tariff">Full and Complete Trade Deal</a>" with the Republic of Korea, worth $450 billion.
Jerome Powell announced the Federal Reserve Open Market Committee&#8217;s decision to keep the interest rates unchanged on Wednesday, with Michelle Bowman and Christopher Waller <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46733603/fed-holds-trump-powell-waller-bowman-interest-rates">dissenting the decision</a>. This was the first dual dissent from Fed board members since 1993. 
Apart from this, Wall Street is also bracing itself as the tech giants, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) will be reporting earnings today.
Meanwhile, the 10-year Treasury bond yielded 4.36% and the two-year bond was at 3.93%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 59% likelihood of the Federal Reserve keeping the current interest rates unchanged for the Sept. 17 decision. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.39%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.00%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.34%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.17%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Thursday. The SPY was up 1.10% at $640.85&nbsp;\, while the QQQ advanced 1.38% to $575.87, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Wednesday, information technology and utilities stocks bucked the overall market trend, closing the session higher, while materials, real estate, and energy stocks recorded the biggest losses among S&amp;P 500 sectors.
U.S. stocks settled lower overall, after Federal Reserve Chair Powell stated &#8220;no decision&#8221; had been made on a September rate cut.
Individually, Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) shares jumped around 27% after reporting better-than-expected second-quarter EPS and sales. Conversely, Avis Budget Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) fell 15% following worse-than-expected quarterly EPS and sales.
On the economic data front, U.S. pending home sales declined by 0.8% from the previous month in May, following a 1.8% gain in April.
The U.S. economy expanded at an annualized rate of 3% in the second quarter, rebounding from a 0.5% contraction in the previous quarter. Private businesses in the U.S. added 104,000 jobs in July, surpassing market estimates of a 75,000 increase.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.15%</td>
<td>21,129.67</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.12%</td>
<td>6,362.90</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.38%</td>
<td>44,461.28</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.47%</td>
<td>2,232.40</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Brian Rehling, the head of global fixed income strategy at Wells Fargo, said that market sentiment is favorable for risk assets, but things can always change.
He advised the investors to &#8220;consider rebalancing portfolios to take advantage of all-time highs in many markets.&#8221;
He highlighted that risk assets continue to hit new milestones, underscoring a resilient economy. The S&amp;P 500, Nasdaq Composite, and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recently hit new all-time highs.
&#8220;It's hard to find a risk asset that has not done well this year with major indexes up significantly year-to-date, highlighting a favorable backdrop for investors,&#8221; he said.
According to him, several factors are contributing to this positive momentum.
He said, &#8220;Corporate earnings have exceeded expectations at the highest rate in recent years, particularly in technology and health care. Recent trade developments, including deals with the European Union and Japan, have helped alleviate some global trade uncertainties, supporting market sentiment. Additionally, the Federal Reserve is likely to lower interest rates this fall, which would be conducive to growth, encouraging business expansion and consumer spending.&#8221;
Overall, these elements, as per Rehling, paint an encouraging picture for risk assets where innovation in areas like artificial intelligence continues to drive value creation.
However, he highlighted that &#8220;Markets do not rise indefinitely without interruptions; periodic pullbacks — such as corrections of 10% or more — are a normal part of the cycle and occur somewhat regularly.&#8221;
Meanwhile, Ryan Detrick of Carson Research highlighted in a memo that one of the most popular economic indicators is the Conference Board's Leading Economic Index (LEI), and it currently points to a recession.
However, he pointed out that this index did not reflect the overall economy and cited his own proprietary LEI.
&#8220;Right now, our version of the LEI says the U.S. economy is growing below trend, i.e., it's slowing, but the index is nowhere close to recession-like levels. At least for now,&#8221; he stated.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul class="wp-block-list">
<li>The initial jobless claims data for the week ended July 26, the second quarter&#8217;s Employment Cost Index data, June personal income, spending, and the headline and core PCE Index data will all be released at 8:30 a.m. ET.</li>
<li>July&#8217;s Chicago Business Barometer (PMI) will be out by 9:45 a.m. ET.</li>
<li></li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) was up 0.22% in premarket on Thursday as analysts expect it to report earnings of $1.58 per share on revenue of $11.31 billion before the opening bell.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was slightly below the flatline by 0.005% as it is expected to report earnings after the closing bell. Analysts estimate earnings of $1.42 per share on revenue of $89.04 billion.</li>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) jumped 3.44% as analysts expect it to report earnings of $1.31 per share on revenue of $161.87 billion before the opening bell.</li>
<li>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) jumped 11.50% after reporting better-than-expected second-quarter financial results, issuing third-quarter sales guidance above estimates.</li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) gained 8.53% after reporting better-than-expected fourth-quarter financial results and issuing a strong forecast for the current quarter.</li>
<li>Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) declined 6.54% as it missed the first-quarter revenue estimate of $1.055 billion, with the sales coming in at $1.053 billion. The adjusted earnings of 35 cents per share were in line with the analyst estimates.</li>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) fell 4.88% despite better-than-expected third quarter results as its phone-related sales rose 7% to $6.33 billion, lower than the analyst estimate of $6.48 billion</li>
<li>VerifyMe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) surged 50.10% after its subsidiary, PeriShip Global, LLC (a logistics provider), entered into a UPS Digital Channel Program Agreement with United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) and UPS Worldwide Forwarding, Inc.</li>
<li>Confluent Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) dropped 29.66% after announcing a $200 million investment aimed at expanding its global partner ecosystem.</li>
<li>IMPINJ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) climbed 21.10% after reporting second-quarter results as its revenue and adjusted EPS exceeded the company&#8217;s guidance.</li>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) was 2.60% higher as Cathie Wood&#8217;s Ark Invest acquired 3,351 AMD shares. This purchase aligns with AMD's recent momentum, as the company raised the price of its MI350 AI chip by $10,000, bringing it to $25,000 per unit.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.07% to hover around $70.05 per barrel.
Gold Spot US Dollar rose 1.12% to hover around $3,312.99 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.10% at the 99.7160 level.
Asian markets ended on a mixed note on Wednesday, as Japan's Nikkei 225 and India's S&amp;P BSE Sensex indices rose. While China&#8217;s CSI 300, Hong Kong's Hang Seng, South Korea's Kospi, and Australia's ASX 200 indices fell. European markets were mostly higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46748274/qualcomm-is-biggest-beneficiary-for-smart-glasses-powering-designs-for-meta-oakley-ray-ban-best-one-for-now-says-expert">Qualcomm Is &#8216;Biggest Beneficiary&#8217; For Smart Glasses—Powering Designs For Meta, Oakley, Ray-Ban: &#8216;Best One For Now,&#8217; Says Expert</a></li>
</ul>
Photo courtesy: Shutterstock

CFLT

VRME

WING

Stock Market Today: S&P 500, Nasdaq To Open Higher After Robust Meta, Microsoft Earnings—Investors Await Apple, Amazon Results

AAMI

ACCO

AGCO

AGIO

ALGM

ALNY

APLS

APPF

ARGX

ASUR

ATEC

ATHM

AUPH

AXTI

BBVA

BCPC

BFAM

BIGC

BJRI

BOOT

BSAC

CABO

CACC

CCCS

CCEC

CDRO

CIGI

CLAR

CMPS

CMRE

COHN

COHU

COLM

CORT

CRAI

CUBE

CVCO

CWST

DFIN

DINO

DOUG

DSGR

Earnings Scheduled For July 31, 2025

The CNN Money Fear and Greed index showed some decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Wednesday.
U.S. stocks settled lower on Wednesday, with the Dow Jones index falling more than 150 points during the session after Federal Reserve Chair Jerome Powell said "no decision" has been made on a September rate cut.
On Wednesday, the Federal Reserve held interest rates steady at 4.25%-4.50% as expected, yet two members broke ranks to support a rate cut, marking the most divided Fed meeting in over three decades.
Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) shares jumped around 27% on Wednesday after the company reported better-than-expected second-quarter EPS and sales. Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) fell 15% following worse-than-expected quarterly EPS and sales.
On the economic data front, U.S. pending home sales declined by 0.8% from the previous month in May, following a 1.8% gain in April. The U.S. economy expanded at an annualized rate of 3% in the second quarter following a 0.5% contraction in the previous quarter. Private businesses in the U.S. added 104,000 jobs in July, compared to market estimates of a 75,000 increase.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, real estate and energy stocks recording the biggest losses on Wednesday. However, information technology and utilities stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by 172 points to 44,461.28 on Wednesday. The S&amp;P 500 fell 0.12% to 6,362.90, while the Nasdaq Composite gained 0.15% to 21,129.67 during Wednesday's session.
Investors are awaiting earnings results from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 66.7, the index remained in the &#8220;Greed&#8221; zone on Wednesday, versus a prior reading of 68.1.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46733987/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to report quarterly earnings at $1.42 per share on revenue of $89.04 billion after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Apple shares fell 0.2% to $208.66 in after-hours trading.</li>
<li>Analysts are expecting Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to have earned $1.31 per share on revenue of $161.87 billion for the latest quarter. The company will release earnings after the closing bell. Amazon shares rose 3.1% to $237.42 in after-hours trading.</li>
<li>Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported better-than-expected second-quarter financial results and issued third-quarter sales guidance above estimates. Meta reported second-quarter revenue of $47.52 billion, beating analyst estimates of $44.58 billion, according to Benzinga Pro. The company reported second-quarter earnings of $7.14 per share, beating estimates of $5.79 per share. Meta shares surged 11.5% to $775.10 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported better-than-expected fourth-quarter financial results and issued strong forecast for the current quarter. Microsoft reported fourth-quarter revenue of $76.44 billion, up 17% year-over-year. The revenue total beat a Street consensus estimate of $73.80 billion according to data from Benzinga Pro. The company reported fourth-quarter earnings per share of $3.65, beating a Street consensus estimate of $3.37. Microsoft shares jumped 8.3% to $555.74 in the after-hours trading session.</li>
<li>Analysts expect Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) to post quarterly earnings at $1.58 per share on revenue of $11.31 billion before the opening bell. Bristol-Myers Squibb shares rose 0.2% to $46.08 in after-hours trading.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46733987/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday

Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) is set to give its latest quarterly earnings report on Thursday, 2025-07-31. Here's what investors need to know before the announcement.
Analysts estimate that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.15. 
Anticipation surrounds Bristol-Myers Squibb's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.31 in the last quarter, leading to a 1.62% drop in the share price on the following day.
Here's a look at Bristol-Myers Squibb's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.49</td>
<td>1.47</td>
<td>1.49</td>
<td>1.63</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.80</td>
<td>1.67</td>
<td>1.80</td>
<td>2.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753884122_0.png" alt="eps graph" />
<h3>Market Performance of Bristol-Myers Squibb's Stock</h3>
Shares of Bristol-Myers Squibb were trading at $46.86 as of July 29. Over the last 52-week period, shares are down 2.67%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on Bristol-Myers Squibb</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Bristol-Myers Squibb.
Analysts have given Bristol-Myers Squibb a total of 1 ratings, with the consensus rating being Underperform. The average one-year price target is $34.0, indicating a potential 27.44% downside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Zoetis, Teva Pharmaceutical Indus and Viatris, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Zoetis, with an average 1-year price target of $173.75, suggesting a potential 270.79% upside.</li>
<li>Analysts currently favor an Buy trajectory for Teva Pharmaceutical Indus, with an average 1-year price target of $23.4, suggesting a potential 50.06% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Viatris, with an average 1-year price target of $10.0, suggesting a potential 78.66% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Zoetis, Teva Pharmaceutical Indus and Viatris, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Underperform</td>
<td>-5.60%</td>
<td>$8.17B</td>
<td>14.57%</td>
</tr>
<tr>
<td>Zoetis</td>
<td>Neutral</td>
<td>1.37%</td>
<td>$1.60B</td>
<td>13.39%</td>
</tr>
<tr>
<td>Teva Pharmaceutical Indus</td>
<td>Buy</td>
<td>1.89%</td>
<td>$1.88B</td>
<td>3.68%</td>
</tr>
<tr>
<td>Viatris</td>
<td>Neutral</td>
<td>-11.17%</td>
<td>$1.16B</td>
<td>-17.74%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Bristol-Myers Squibb ranks at the bottom for revenue growth and gross profit, while it is in the middle for return on equity. The consensus rating for the company is 'Underperform'.
<h3>Get to Know Bristol-Myers Squibb Better</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Bristol-Myers Squibb: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Bristol-Myers Squibb's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -5.6%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bristol-Myers Squibb's net margin excels beyond industry benchmarks, reaching 21.93%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bristol-Myers Squibb's ROE stands out, surpassing industry averages. With an impressive ROE of 14.57%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bristol-Myers Squibb's ROA stands out, surpassing industry averages. With an impressive ROA of 2.65%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 2.95, Bristol-Myers Squibb faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/BMY/earnings">To track all earnings releases for Bristol-Myers Squibb visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bristol-Myers Squibb Earnings Preview

<ul>
<li>Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus</li>
<li>Bain Capital leads $300 million financing commitment</li>
</ul>
Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>, "BMS"))) and Bain Capital today announced the creation of a new independent biopharmaceutical company ("NewCo") focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital.
The NewCo has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that each target promising mechanisms in autoimmune diseases. The most advanced assets in the NewCo's portfolio are afimetoran, an oral, potential best-in-class TLR7/8 inhibitor that is currently being studied in a Phase 2 clinical trial for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor, which successfully established proof-of-concept in a positive plaque psoriasis Phase 2 trial. Other licensed assets include BMS-986326, a novel, potential best-in-class, IL2 fusion protein that is currently being studied in Phase 1 clinical trials for SLE and atopic dermatitis, and BMS-986481 and BMS-986498, two Phase 1-ready biologics targeting the IL18 and IL10 pathways respectively.
The assets licensed to NewCo reflect the strength of BMS's scientific innovation and hold promise to address unmet needs for patients with autoimmune diseases. As part of the agreement, BMS will retain a nearly 20 percent equity stake in NewCo and will be entitled to royalties and milestones tied to the success of each asset. Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer at BMS, will also serve on NewCo's Board of Directors. This transaction reflects BMS's strategic shift in Immunology research to focus on assets that have the potential to reset the immune system and promote tissue repair. It also further demonstrates the company's sharpened strategy to invest in areas where BMS is best positioned to lead, while enabling the continued development of promising medicines.

Contracts

Bristol Myers And Bain Capital Launch $300M Autoimmune Biotech With 5 In-Licensed Immunology Assets, Including Late-Stage Lupus Drug

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings <a href="https://www.benzinga.com/general/biotech">from its latest clinical trial.</a>
Recognify Life Sciences announced data from a randomized, double-blind, placebo-controlled Phase 2b trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">associated with schizophrenia (CIAS)</a>. Recognify is a strategic investment of ATAI Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>).
<ul class="wp-block-list">
<li>ATAI stock is tumbling in today&#8217;s session. <a href="https://www.benzinga.com/quote/ATAI" target="_blank" rel="noreferrer noopener">Check the price action here.</a></li>
</ul>
The trial did not meet its primary endpoint of improvement on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) neurocognitive composite score at Week 6.
Also Read: <a target="_blank" href="https://www.benzinga.com/cannabis/25/07/46194289/atai-life-sciences-and-merger-partner-set-up-psychedelic-depression-therapy-with-encouraging-late-stage-data" rel="noreferrer noopener">Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data</a>
The company on Monday said the inidascamine demonstrated a modest but consistent numerical improvement across the overall MCCB neurocognitive composite and multiple individual subdomains, including Symbol Coding, Speed of Processing, and Verbal Learning<a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46643996/recognify-life-sciences-provides-update-on-phase-2b-trial-of-inidascamine-in-patients-with-cogniti" rel="noreferrer noopener"> (immediate recall)</a>.
Directionally positive effects were also observed on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a real-world functional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio" rel="noreferrer noopener">cognitive capacity measure</a>.
Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies.
No evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are side effects commonly associated with schizophrenia treatments.
The study enrolled 242 patients.
Recognify plans to present additional results from the study at upcoming scientific meetings and will continue to evaluate strategic options for inidascamine based on the totality of data.
In November 2024, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
In September 2024, the FDA approved Bristol Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for <a href="https://www.benzinga.com/pressreleases/24/09/b41059140/u-s-food-and-drug-administration-approves-bristol-myers-squibbs-cobenfy-xanomeline-and-trospium-ch" target="_blank" rel="noreferrer noopener">schizophrenia in adults</a>.
Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1&nbsp;and M4&nbsp;receptors in the brain without blocking D2&nbsp;receptors.
ATAI Price Action: ATAI Life Sciences shares were down 9.38% at $3.23 at the time of publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46657092/can-american-airlines-navigate-financial-turbulence-ahead" target="_blank" rel="noreferrer noopener">Can American Airlines Navigate Financial Turbulence Ahead?</a></li>
</ul>
Photo: Shutterstock

ATAI

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Investor sentiment around several major stocks got a boost this week thanks to upbeat commentary from Jim Cramer <a href="https://www.benzinga.com/topic/jim-cramer">and fresh analyst support</a>.
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Cramer praised both Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) and CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>).
&#8220;Marvin Ellison [CEO of Lowe&#8217;s] is hitting the ball,&#8221; Cramer added <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">with a buy recommendation</a>. &#8220;He's doing his best.&#8221;
Supporting his view, Guggenheim analyst Steven Forbes, on July 22, reiterated Lowe&#8217;s Companies with a Buy and maintained a $300 price target.
When asked about CrowdStrike, he said, &#8220;Take out your cost basis, and then you're going to let the rest run. And I'll see you at $1000.&#8221;
Macquarie analyst Steve Koenig, on July 17, initiated coverage on CrowdStrike with a Neutral rating and announced a price target of $465.
&#8220;We're still on the verge of finding out what this Seagen acquisition does,&#8221; Cramer said when asked about Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). &#8220;Let's give Dr. Bourla [CEO of Pfizer] two more quarters.&#8221;
As per the recent news, Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer alliance, on July 17, announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance's patient resource, Eliquis 360 Support, on Thursday. Eliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.
Price Action:
<ul class="wp-block-list">
<li>Pfizer shares gained 0.9% to settle at $25.36 on Wednesday.</li>
<li>CrowdStrike shares fell 2.1% to close at $461.52.</li>
<li>Lowe's shares gained 1.3% to settle at $228.61 on Wednesday.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

CRWD

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000'

Bristol-Myers Squibb's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) short percent of float has risen 17.58% since its last report. The company recently reported that it has 39.45 million shares sold short, which is 1.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bristol-Myers Squibb Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753300828_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bristol-Myers Squibb has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bristol-Myers Squibb's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Bristol-Myers Squibb's Recent Short Interest

In the current session, the stock is trading at $46.90, after a 0.45% spike. Over the past month, Bristol-Myers Squibb Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stock increased by 1.92%, and in the past year, by 7.33%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1753210824_0.png" alt="Past Year Chart" />

<h3>A Look at Bristol-Myers Squibb P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 29.12 in the Pharmaceuticals industry, Bristol-Myers Squibb Inc. has a lower P/E ratio of 17.42. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1753210824_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Bristol-Myers Squibb Inc's Price Over Earnings

AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) announced on Tuesday that it will invest $50 billion in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">United States by 2030</a>.
The investment will create new, highly skilled direct and indirect jobs nationwide, the company <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html" rel="noreferrer noopener">said</a>.
The cornerstone of this landmark investment is a new multi-billion-dollar U.S. manufacturing facility that will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small-molecule products.
The new centre will produce small molecules, peptides, and oligonucleotides.
This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned for the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. It will leverage AI, automation, and data analytics to optimize production.
<h2 class="wp-block-heading">What Does The Investment Include?</h2>
The $50 billion investment across R&amp;D and manufacturing footprint in the U.S. over the next five years also includes:
<ul class="wp-block-list">
<li>Expansion of R&amp;D facility in Gaithersburg, Maryland</li>
<li>R&amp;D centre in Kendall Square, Cambridge, Massachusetts</li>
<li>Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials.</li>
</ul>
The company said collectively, these investments will help deliver AstraZeneca's <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38936595/astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion" rel="noreferrer noopener">ambition of reaching $80 billion</a> in Total Revenue by 2030, of which 50% would be generated in the U.S.
Howard Lutnick, U.S. Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores."
<a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S. Most recently, Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) said that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46529101/biogen-bets-big-on-2-billion-expansion-to-boost-us-drug-manufacturing" rel="noreferrer noopener">Triangle Park (RTP)</a>.
Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" rel="noreferrer noopener">domestic medicine production</a>.
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" rel="noreferrer noopener">the next four years</a>.
Medtech firm&nbsp;Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" rel="noreferrer noopener">over the next five years</a>.
Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>. Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S.&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" rel="noreferrer noopener">over the next five years</a>.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>. Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/pharmaceuticals" rel="noreferrer noopener">the next five years.</a>
Bristol-Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer,&nbsp;<a target="_blank" href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years. Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced it will invest at least&nbsp;$20 billion&nbsp;in&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45419235/sanofi-joins-other-big-pharma-to-navigate-potential-tariff-impact-with-at-least-20-billion-in-investments-through-2030" rel="noreferrer noopener">U.S.&nbsp;through 2030</a>. The bulk of the spending will go to R&amp;D and U.S. manufacturing.
Price Action: AZN stock is up 2.34% at $70.33 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46551856/pony-ai-stock-surges-as-autonomous-system-hits-key-milestone" target="_blank" rel="noreferrer noopener">Pony AI Stock Surges As Autonomous System Hits Key Milestone</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

REGN

RHHBY

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

Press Releases

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Bristol Myers Squibb Announces Dividend

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Comments

Bristol-Myers Squibb

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL